Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions
/in International Publications, Newcastle Disease Virus /von 2007-01-15 / Cancer Res. 2007 Jan;67(2):429-32Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics
/in Glioblastoma, International Publications /von 2007-01-15 / Clin. Cancer Res. 2007 Jan;13(2 Pt 1):566-575p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2007-01-10 / J. Virol. 2007 Mar;81(6):2817-30Induction of dendritic cell-mediated immune responses against canine malignant melanoma cells
/in International Publications, Malignant Melanoma /von 2007-01-08 / Vet. J. 2008 Jan;175(1):126-9Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells
/in Breast Cancer, International Publications /von 2007-01-03 / Vaccine 2007 Mar;25(14):2610-9Vitamin E analogues and immune response in cancer treatment
/in International Publications, Micronutrients /von 2007-01-01 / Vitam Horm 2007;76:463-91[Immunotherapy and malignant mesothelioma: clinical perspectives]
/in International Publications, Malignant Pleural Mesothelioma /von 2007-01-01 / Bull Cancer 2007 Jan;94(1):23-31Results of a pilot trial of immunotherapy with dendritic cells pulsed with autologous tumor lysates in patients with advanced cancer
/in Breast Cancer, International Publications, Malignant Melanoma /von 2007-01-01 / Tumori 2007 Jan-Feb;93(1):26-30[Induction of specific CTL by DC from axillary lymph node of patients with breast cancer]
/in Breast Cancer, International Publications /von 2007-01-01 / Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2007 Jan;23(1):60-2
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution